Enterprise Therapeutics Ltd

About Enterprise Therapeutics Ltd

Enterprise Therapeutics is a clinical stage biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases such as cystic fibrosis, asthma, and COPD. Their mission is to develop new medicines that target the underlying mechanisms of mucus congestion, reducing lung infections and improving patient quality of life.

Products & Services

ETD001:A novel inhaled ENaC blocker for the treatment of cystic fibrosis, currently in Phase 2 clinical trials.

Specialties

Respiratory disease therapies Drug discovery and development Muco-regulatory approaches Treatment of cystic fibrosis, asthma, and COPD

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 33100000 MR: - FA: £26 million ($33.1 million USD) FAN: 33100000	D: 2024-01-30 FD: 2024-01-30	6 investors

Series B Latest

2024-01-30

$33.1M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Richard C Boucher

James Moeser Eminent Professor of Medicine

J

Jane Davies

Professor of Paediatric Respirology and Experimental Medicine

L

Luis Galietta

Professor

W

Wisia Wedzicha

Professor of Respiratory Medicine

S

Simon Ward

Sêr Cymru Professor in Translational Drug Discovery and Director of the Medicines Discovery Institute at Cardiff University

S

Scott Donaldson

Hubert E. Hatcher Family Distinguished Professor of Medicine

View 23 more team members with Pro

Unlock Full Team Directory

Recent News